Dergiler / European Journal of Breast Health / 2021 / Cilt: 17 - Sayı: 2

Breast Cancer Management During the COVID-19 Pandemic: The Senologic International Society Survey

Sayfa
188–196
Yayın Tarihi
2022-10-18
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Only women aged over 65 with BC under treatment and comorbidities require adaptation of their cancer management.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: In early 2020, the spread of coronavirus disease-2019 (COVID-19) led the World Health Organization to declare this disease a pandemic.
📊
Temel Bulgular & Veri:Initial epidemiological data showed that patients with cancer were at high risk of developing severe forms of COVID-19.
💡
Sonuç & Katkı:Only women aged over 65 with BC under treatment and comorbidities require adaptation of their cancer management.
🔬Tür:Uygulamalı Anket & Alan Araştırması
📍Kapsam:2020 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

Objective: In early 2020, the spread of coronavirus disease-2019 (COVID-19) led the World Health Organization to declare this disease a pandemic. Initial epidemiological data showed that patients with cancer were at high risk of developing severe forms of COVID-19. National scientific societies published recommendations modifying the patients’ breast cancer (BC) management to preserve, in theory, quality oncologic care, avoiding the increased risk of contamination. The Senology International Society (SIS) decided to take an inventory of the actions taken worldwide. This study investigates COVID-19-related changes concerning BC management and analyzes the will to maintain them after the pandemic, evaluating their oncological safety consequences. Materials and Methods: SIS network members participated in an online survey using a questionnaire (Microsoft® Forms) from June 15th to July 31st, 2020. Results: Forty-five responses from 24 countries showed that screening programs had been suspended (68%); magnetic resonance imagines were postponed (73%); telemedicine was preferred when possible (71%). Surgeries were postponed: reconstructive (77%), for benign diseases (84%), and in patients with significant comorbidities (66%). Chemotherapy and radiotherapy protocols had been adapted in 28% of patients in both. Exception for telemedicine (34%), these changes in practice should not be continued. Conclusion: The SIS survey showed significant changes in BC’s diagnosis and treatment during the first wave of the COVID-19 pandemic, but most of these changes should not be maintained. Indeed, women have fewer severe forms of COVID-19 and are less likely to die than men. The risk of dying from COVID-19 is more related to the presence of comorbidities and age than to BC. Stopping screening and delaying treatment leads to more advanced stages of BC. Only women aged over 65 with BC under treatment and comorbidities require adaptation of their cancer management.

🔖

Bu Makaleye Atıf Yap

LODI, M., ÖZMEN, V., ÖZBAŞ, S., MATHELIN, C., ANYANWU, S., MAGHALES-COSTA, M., PIENKOWSKI, T., SCHNEEBAUM, S., AME, S., AVISAR, E., BREITLING, K., ANIE, H. A., CONCEİÇAO, J. C., DUPONT, V., ELDER, E., ELFGEN, C., ELONGE, T., Edelmiro, E. (2022). Breast Cancer Management During the COVID-19 Pandemic: The Senologic International Society Survey. European Journal of Breast Health, Cilt: 17 - Sayı: 2, 188–196. https://ajindex.com/articles/510713

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (11)

  1. Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020
  2. (PMID: 32066541) [Crossref] 2. Miyashita H, Mikami T, Chopra N, Yamada T, Chernyavsky S, Rizk D, et al. Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York City. Ann Oncol 2020
  3. (PMID: 32330541) [Crossref] 3. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018
  4. (PMID: 30207593) [Crossref] 4. Darai E, Mathelin C, Gligorov J. Breast cancer management during the COVID 19 pandemic: French guidelines. Eur J Breast Health 2020
  5. (PMID: 32656513) [Crossref] 5. Soran A, Gimbel M, Diego E. Breast cancer diagnosis, treatment and follow-up during COVID-19 pandemic. Eur J Breast Health 2020
  6. (PMID: 32285027) [Crossref] 6. Cakmak GK, Ozmen V. Sars-CoV-2 (COVID-19) outbreak and breast cancer surgery in Turkey. Eur J Breast Health 2020
  7. (PMID: 32285026) [Crossref] 7. Fu L, Wang B, Yuan T, Chen X, Ao Y, Fitzpatrick T, et al. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: a systematic review and meta-analysis. J Infect 2020
  8. (PMID: 32283155) [Crossref] 8. de Azambuja E, Brandão M, Wildiers H, Laenen A, Aspeslagh S, Fontaine C, et al. Impact of solid cancer on in-hospital mortality overall and among different subgroups of patients with COVID-19: a nationwide, population-based analysis. ESMO Open 2020
  9. e000947. doi: 10.1136/ esmoopen-2020-000947. (PMID: 32978251) [Crossref] 9. de Azambuja E, Trapani D, Loibl S, Delaloge S, Senkus E, Criscitiello C, et al. ESMO Management and treatment adapted recommendations in the COVID-19 era: breast cancer. ESMO Open 2020
  10. 5(Suppl 3): e000793. doi: 10.1136/esmoopen-2020-000793. (PMID: 32439716) [Crossref] 10. Seely JM, Scaranelo AM, Yong-Hing C, Appavoo S, Flegg C, Kulkarni S, et al. COVID-19: safe guidelines for breast imaging during the pandemic. Can Assoc Radiol J 2020
  11. (PMID: 32452700) [Crossref] 11. Lin DD, Meghal T, Murthy P, Mo L, D’Silva A, Huang Y, et al. Chemotherapy treatment modifications during the COVID-19 outbreak at a Community Cancer Center in New York City. JCO Glob Oncol 2020: 1298-1305. (PMID: 32795196) [Crossref] 12. Spencer K, Jones CM, Girdler R, Roe C, Sha